• 1
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 19071917.
  • 2
    Ganne-Carrie N, Trinchet JC. Systemic treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004; 3: 275281.
  • 3
    Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 2004; 7: 409418.
  • 4
    Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4: 333339.
  • 5
    Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12: 228237.
  • 6
    Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004; 10: 777783.
  • 7
    Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1: 287299.
  • 8
    Lindemann RK, Johnstone RW. Histone deacetylase inhibitors: promising candidates for chemotherapeutic drugs. Gene Ther Mol Biol 2004; 8: 6174.
  • 9
    Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45: 495528.
  • 10
    Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Göttlicher M, et al. Histone deacetylase inhibitors valproate and ITF2357 induce apoptosis on hepatoma cells, but not on primary hepatocytes. J Hepatol 2005; 42: 210217.
  • 11
    Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG, et al. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 2002; 36: 233240.
  • 12
    Yamashita Y, Shimada M, Harimoto N, Rikimaru T, Shirabe K, Tanaka S, et al. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 2003; 103: 572576.
  • 13
    Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, et al. NK cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65: 63216329.
  • 14
    Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 7176.
  • 15
    Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukaemia cells. Nat Med 2005; 11: 7784.
  • 16
    Okano H, Shiraki K, Inoue H, Kawakita T, Yamanaka T, Deguchi M, et al. Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 2003; 83: 10331043.
  • 17
    Weiss TS, Pahernik S, Scherueb I, Jauch KW, Thasler, WE. Cellular damage to human hepatocytes through repeated application of 5-aminolevulinic acid. J Hepatol 2003; 38: 476482.
  • 18
    Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, Gregor M, et al. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res 2003; 63: 23692372.
  • 19
    Bitzer M, Prinz F, Bauer M, Spiegel M, Neubert WJ, Gregor M, et al. Sendai virus infection induces apoptosis through activation of caspase-8 (FLICE) and caspase-3 (CPP32). J Virol 1999; 73: 702708.
  • 20
    Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis inducing ligand. Nat Med 2000; 6: 564567.
  • 21
    Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383385.
  • 22
    Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155162.
  • 23
    Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, et al. Chemotherapeutic agents augment TRAIL-induced apaoptosis in human hepatocellular carcinoma cell lines. HEPATOLOGY 2000; 32: 482890.
  • 24
    Kim YS, Schwabe RF, Qian T, Lemasters JJ, Brenner DA. TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells. HEPATOLOGY 2002; 36: 14981508.
  • 25
    Chen XP, He SQ, Wang HP, Zhao YZ, Zhang WG. Expression of TNF-related apoptosis-inducing Ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing Ligand in human hepatocellular carcinoma. World J Gastroenterol 2003; 11: 24332440.
  • 26
    Villar-Garea A, Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 2004; 112: 171178.
  • 27
    Hess-Stumpp H. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol 2005; 84: 109121.
  • 28
    Schuchmann M, Galle PR. Sensitizing to apoptosis-sharpening the medical sword. J Hepatol 2004; 2: 335336.
  • 29
    Ogawa K, Yasumura S, Atarashi Y, Minemura M, Miyazaki T, Iwamoto M, et al. Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells. J Hepatol 2004; 2: 27884.
  • 30
    Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815818.
  • 31
    Guo F, Sigua C, Tao J, Bali P, George P, Li Y, et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signalling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004; 7: 25802589.
  • 32
    Shin EC, Seong YR, Kim CH, Kim H, Ahn YS, Kim K, et al. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med 2002; 2: 114122.
  • 33
    Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 10: 190195.
  • 34
    Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 6: 28332840.
  • 35
    Burns TF, El-Deiry WS. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem 2001; 41: 3787937886.
  • 36
    Bin L, Li X, Xu LG, Shu HB. The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis. FEBS Lett 2002; 1–2: 3740.
  • 37
    Hernandez A, Thomas R, Smith F, Sandberg J, Kim S, Chung DH, et al. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery 2001; 130: 265272.
  • 38
    Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004; 24: 85418555.
  • 39
    Li H, Wu X. Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells. Biochem Biophys Res Commun 2004; 324: 860867.
  • 40
    Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005; 102: 36973702.
  • 41
    Ikeguchi M, Hirooka Y. Expression of c-myc mRNA in hepatocellular carcinomas, noncancerous livers, and normal livers. Pathobiology 2004; 71: 281286.
  • 42
    Chan KL, Guan XY, Ng IO. High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. Hum Pathol 2004; 35: 13241331.